News - Boehringer Ingelheim, Pradaxa

Filter

Popular Filters

1 to 25 of 31 results

High price of novel antithrombotics a major deterrent to patient access in China

High price of novel antithrombotics a major deterrent to patient access in China

10-06-2014

The high cost of therapy remains a significant barrier for uptake of novel oral anticoagulants (NOACs)…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularChinaEliquisMarkets & MarketingPharmaceuticalPradaxaPricingWarfarin SodiumXarelto

Boehringer’s Pradaxa gains added indication in Europe

Boehringer’s Pradaxa gains added indication in Europe

06-06-2014

German family-owned pharma major Boehringer Ingelheim said today that its blood thinner Pradaxa (dabigatran…

Boehringer IngelheimCardio-vascularEuropePharmaceuticalPradaxaRegulation

Boehringer Ingelheim agrees $650 million comprehensive settlement of US Pradaxa litigation

Boehringer Ingelheim agrees $650 million comprehensive settlement of US Pradaxa litigation

28-05-2014

German family-owned pharma major Boehringer Ingelheim says it has reached a comprehensive settlement…

Boehringer IngelheimCardio-vascularFinancialLegalPharmaceuticalPradaxaUSA

FDA finds favorable risk:benefit balance for Boehringer’s Pradaxa

18-05-2014

As part of its ongoing review, the US Food and Drug Administration last week released latest findings…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaRegulationUSA

US FDA clears Boehringer Ingelheim’s Pradaxa for additional indications

US FDA clears Boehringer Ingelheim’s Pradaxa for additional indications

07-04-2014

The US Food and Drug Administration has approved German family-owned pharma major Boehringer Ingelheim’s…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulationUSA

First human data show promise of Boehringer’s specific antidote for Pradaxa-induced anticoagulation

First human data show promise of Boehringer’s specific antidote for Pradaxa-induced anticoagulation

19-11-2013

Presented for the first time at the American Heart Association’s (AHA) Scientific Sessions, results…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularEliquisPharmaceuticalPradaxaResearchXarelto

Boehringer analysis finds better outcome for Pradaxa compared to warfarin

Boehringer analysis finds better outcome for Pradaxa compared to warfarin

08-10-2013

Boehringer Ingelheim has released new data showing better survival prognosis following a major bleeding…

Boehringer IngelheimHematologyPharmaceuticalPradaxaResearch

Boehringer Ingelheim plans to expand body of evidence for Pradaxa

04-09-2013

German family-owned drug major Boehringer Ingelheim has announced new milestones for the novel oral anticoagulant…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaResearch

Pradaxa sNDA for DVT and PE accepted by FDA

28-08-2013

The US Food and Drug Administration has accepted for review German independent drug major Boehringer…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulation

FDA confirms views that Boehringer's Pradaxa bleeding rates no higher than for warfarin

19-03-2013

A new perspective from the US Food and Drug Administration states the agency has not changed its recommendations…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaResearch

Positive trials results for Boehringer Ingelheim's Pradaxa for prevention of recurrent DVT and PE

22-02-2013

Findings from the RE-MEDY and RE-SONATE trials investigating German family-owned drug major Boehringer…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaResearch

Brazil's atrial fibrillation market expected to grow at 31% pa over next five years

22-01-2013

The Brazilian market for atrial fibrillation will increase at a rate of 31% per year from 2011 to 2016,…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularDaiichi SankyoEliquisLixianaMarkets & MarketingPharmaceuticalPradaxaSouth AmericaXarelto

Boehringer Ingelheim updates safety info for Pradaxa related to heart valve

21-12-2012

The US subsidiary of German independent drug major Boehringer Ingelheim says that the US prescribing…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulation

Australian review finds more work needed on new anticoagulants

19-12-2012

A report into anticoagulation therapies released yesterday by Australian Minister for Health Tanya Plibersek…

Asia-PacificBoehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingRegulation

Highlights from ASH meeting on Eliquis, Pradaxa, ALN-TMP and ibrutinib

11-12-2012

During the 54th Annual Meeting of the American Society of Hematology (ASH) now taking place in Atlanta,…

ALN-TMPAlnylam PharmaceuticalsBiotechnologyBoehringer IngelheimBristol-Myers SquibbCardio-vascularEliquisibrutinibOncologyPfizerPharmaceuticalPharmacyclicsPradaxaResearch

Serious bleeding risk with Boehringer's Pradaxa no worse than warfarin, says FDA

06-11-2012

In a follow up to a 2011 safety communication, the US Food and Drug Administration has evaluated new…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulationResearch

Pradaxa efficacy and cost effectiveness advantages over Xarelto

27-08-2012

Indirect comparison based on the RE-LYtrial (for family owned German drugmaker Boehringer Ingelheim's…

BayerBoehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingResearchXarelto

Boehringer Ingelheim updates US labelling of Pradaxa for stroke

07-06-2012

Independent German drug major Boehringer Ingelheim has updated the US prescribing information for Pradaxa…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulation

EMA unit backs approval of Jentadueto; Agency updates on Pradaxa

28-05-2012

Independent German drug major Boehringer Ingelheim and US partner Eli Lilly (NYSE: LLY) have received…

Boehringer IngelheimCardio-vascularDiabetesEli LillyEuropeJentaduetoPharmaceuticalPradaxaRegulation

NICE recommends NHS use of Pradaxa

15-03-2012

In final guidance published today (March 15), the UK drug watchdog the National Institute of Health and…

Boehringer IngelheimCardio-vascularEuropePharmaceuticalPradaxaPricingRegulation

UK ABPI gears up for next pricing negotiations; Boehringer breaches code

19-12-2011

The Associations of the British Pharmaceutical Association (ABPI) last Friday brought together pharmaceutical…

Boehringer IngelheimEuropeMarkets & MarketingPharmaceuticalPradaxaPricing

FDA reviews Pradaxa bleeding risk

08-12-2011

Post-marketing reports of serious bleeding events in patients taking Pradaxa (dabigatran etexilate mesylate),…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulation

1 to 25 of 31 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top